Passage BIO Confirms Nasdaq Listing for Common Stock

Ticker: PASG · Form: 8-K · Filed: Jan 5, 2024 · CIK: 1787297

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, corporate-governance

TL;DR

**PASG confirms Nasdaq listing, business as usual.**

AI Summary

Passage BIO, Inc. filed an 8-K on January 5, 2024, to disclose that its Common Stock, with a $0.0001 Par Value Per Share, is registered on The Nasdaq Stock Market LLC (Nasdaq Global Select Market) under the trading symbol PASG. This filing is a routine update, confirming the company's current listing status and compliance with SEC regulations. For investors, this matters because it reaffirms the stock's continued liquidity and visibility on a major exchange, which is fundamental for trading and valuation.

Why It Matters

This filing confirms Passage BIO's continued listing on Nasdaq, ensuring the stock remains easily tradable and accessible to investors.

Risk Assessment

Risk Level: low — This is a routine administrative filing with no new material financial or operational information, indicating very low risk.

Analyst Insight

This filing is purely administrative and does not provide new information that would warrant an immediate investment action. Investors should continue to monitor operational and financial reports for actionable insights.

Key Numbers

Key Players & Entities

FAQ

What is the exact name of the registrant as specified in its charter?

The exact name of the registrant as specified in its charter is PASSAGE BIO, INC.

On what date was the earliest event reported in this 8-K filing?

The date of the earliest event reported in this 8-K filing is January 5, 2024.

What is the trading symbol for Passage BIO, Inc.'s Common Stock?

The trading symbol for Passage BIO, Inc.'s Common Stock is PASG.

On which exchange is Passage BIO, Inc.'s Common Stock registered?

Passage BIO, Inc.'s Common Stock is registered on The Nasdaq Stock Market LLC (Nasdaq Global Select Market).

What is the par value per share for Passage BIO, Inc.'s Common Stock?

The par value per share for Passage BIO, Inc.'s Common Stock is $0.0001.

Filing Stats: 511 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-01-05 16:05:59

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 5, 2024, Passage Bio, Inc. updated its corporate presentation. A copy of the corporate presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act. The information contained in this Item 7.01 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Corporate Presentation. 104 Cover Page Interactive Data File (formatted as Inline XBRL). 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PASSAGE BIO, INC. Date: January 5, 2024 By: /s/ Kathleen Borthwick Kathleen Borthwick Interim Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing